Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serono and Genmab A/S have signed a worldwide agreement to develop and commercialize HuMax-TAC, a monoclonal antibody with potential in T-cell mediated diseases such as autoimmune disorders, inflammatory and hyperproliferative skin disorders and acute transplant rejection.
Subscribe to our email newsletter
Under the agreement, Genmab has granted Serono exclusive worldwide rights to develop and commercialize Genmab’s HuMax-TAC. Genmab will receive an upfront payment of $2 million and is entitled to potential milestone payments of up to $38 million and royalties on sales from any eventual commercialization of the product. Serono will be responsible for all future development costs for HuMax-TAC.
The product is a fully human monoclonal antibody targeting the TAC antigen – also known as CD25, or the interleukin-2 receptor alpha subunit (IL-2Ra) – which is overexpressed by activated T-cells.
“We are committed to the development of novel therapeutics to fulfill significant unmet medical needs,” said Dr Timothy Wells, head of research at Serono. “We believe that HuMax-TAC brings a new dimension to the treatment of many of the key diseases where Serono has a scientific and medical interest.”